Lutetium (177Lu) Oxodotreotide — Drug Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

12 Recruiting

4 Completed trials

14 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 3 Phase II: 7 Phase I/II: 3 Phase IV: 2 Phase I (Other): 1

Oversight events:

2 serious breaches 6 temporary halts 2 unexpected events across 4 trials

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 4 Neuroendocrine tumour 3 Pancreatic neuroendocrine tumour 1 Neuroblastoma 1 Small intestine neuroendocrine tumour 1 Meningioma 1 Small cell lung cancer extensive stage 1

Sponsors using this IMP

Advanced Accelerator Applications 2 Novartis Pharma AG 2 Antwerp University Hospital 1 Centre Hospitalier Universitaire De Bordeaux 1 CHRU De Nancy 1 Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi 1 Fundacion De investigacion De Hm Hospitales 1 Grupo Espanol De Tumores Neuroendocrinos 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Institut Regional Du Cancer De Montpellier 1 Karolinska University Hospital 1 Oncopole Claudius Regaud 1

All trials

16 total

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting

2024-513185-19-00 Phase I/II 8 countries Novartis Pharma AG
Adjuvant radioligand therapy in neuroendocrine tumors Recruiting

2024-518236-36-00 Phase III 1 country Philipps-Universitaet Marburg
Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting

2024-518325-15-00 Phase III 7 countries Novartis Pharma AG
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting

2024-512132-29-00 Phase II 1 country Swiss Group for Clinical Cancer Research
Lu177-Dotatate every 16 weeks to reduce adverse events in patients with midgut neuroendocrine tumors Recruiting

2024-517921-14-00 Phase I/II 2 countries Grupo Espanol De Tumores Neuroendocrinos
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr… Recruiting

2023-508400-38-00 Phase II 1 country CHRU De Nancy
Study in children and adolescents for the treatment of recurrent or relapsed solid tumours with the treatment of Lutathera® combined with ol… Recruiting

2024-512613-40-00 Phase I/II 1 country Fundacion De investigacion De Hm Hospitales
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial Recruiting

2023-505884-35-00 Phase IV 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 Phase IV 2 countries Antwerp University Hospital
STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE… Recruiting

2024-511001-28-00 Phase II 1 country Institut Regional Du Cancer De Montpellier
Intra-arterial hepatic (IAH) infusion of radiolabelled somatostatin analogs in GEP-NET patients with dominant liver metastases Recruiting

2024-514785-39-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N Ended

2023-503684-42-00 Phase II 6 countries Karolinska University Hospital
Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs. Ended

2023-507444-37-00 Phase II 3 countries Advanced Accelerator Applications
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended

2023-507443-10-00 Phase III 5 countries Advanced Accelerator Applications
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended

2024-515552-21-00 Phase I (Other) 1 country Oncopole Claudius Regaud

Showing 1–16 of 16 trials

← All drugs A–Z